- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
- Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
- Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
- Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
- Belite Bio to Participate in the BTIG Ophthalmology Day
- Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
- Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
More ▼
Key statistics
On Tuesday, Belite Bio Inc (BLTE:NAQ) closed at 37.00, -23.87% below its 52-week high of 48.60, set on Feb 12, 2024.
52-week range
Open | 33.85 |
---|---|
High | 37.33 |
Low | 33.85 |
Bid | 14.76 |
Offer | 37.38 |
Previous close | 34.48 |
Average volume | 25.00k |
---|---|
Shares outstanding | 29.75m |
Free float | 11.38m |
P/E (TTM) | -- |
Market cap | 1.10bn USD |
EPS (TTM) | -1.24 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 21:15 BST.
More ▼